Glaukos Corporation Reports 50% Revenue Growth to $185.6 Million in Q2 2026

Glaukos Corporation reported significant financial growth in its latest quarterly filing, with net sales reaching $185.6 million for the three months ended June 30, 2026, a 50% increase from $124.1 million in the same period last year. For the first half of 2026, the company generated $336.2 million in net sales, up 46% from $230.8 million in the first half of 2025. The increase in revenue was primarily driven by higher sales volumes of its iDose TR product, which has a higher net sales price compared to other offerings, and a notable rise in international sales, particularly in key markets such as France, the United Kingdom, and Australia.

Despite the revenue growth, Glaukos reported a net loss of $18.4 million for the second quarter of 2026, a slight improvement from a loss of $19.7 million in the same quarter of 2025. For the first half of 2026, the net loss was $38.2 million, compared to $37.8 million in the prior year. The company’s gross margin improved to 82% in the second quarter, up from 78% a year earlier, reflecting better cost management alongside increased sales. Operating expenses also rose, with selling, general, and administrative expenses increasing by 39% to $116.1 million, driven by higher compensation costs and investments in commercial infrastructure.

Strategically, Glaukos has made significant advancements with the commercial launch of its new product, Epioxa, which received FDA approval in 2025. The company began a controlled launch of Epioxa in early 2026 and transitioned commercial efforts from its previous product, Photrexa. Additionally, the U.S. Centers for Medicare & Medicaid Services assigned a unique J-code for Epioxa, effective July 1, 2026, which is expected to streamline billing and reimbursement processes for healthcare providers.

Operationally, Glaukos reported an increase in accounts receivable, which rose to $138.9 million as of June 30, 2026, compared to $108.6 million at the end of 2025. This increase is attributed to extended payment terms associated with the iDose TR and Epioxa products. The company’s cash and cash equivalents totaled $114.5 million, up from $90.8 million at the end of 2025, indicating improved liquidity. Glaukos also plans to invest in expanding its manufacturing capabilities, including a new facility in Huntsville, Alabama, which is expected to incur over $80 million in capital expenditures.

Looking ahead, Glaukos anticipates continued growth driven by the increasing adoption of its products, particularly iDose TR and Epioxa. The company is focused on enhancing its commercial operations and expanding its market presence, while also navigating potential challenges related to global economic conditions and reimbursement landscapes. The management remains optimistic about achieving sustained profitability as it capitalizes on its innovative product pipeline and market opportunities.